Summarized by Masters of Longevity from Longevity Technology.
Investors and researchers debate which longevity research and business ideas merit translation and funding in a conference-focused feature. Expect a curious, investor-minded look at scientific rigor versus market opportunity.
Key Takeaways
- Speakers emphasized shifting investment scrutiny from animal models to human evidence and clinical relevance.
- Steve Horvath advised assessing biological age reversal claims using control groups, context, and the chosen epigenetic clock.
- Panels highlighted consumer longevity demand while warning investors to validate repeatable evidence and sustainable business models.
